Confirmation of Interim Results
15 November 2022
Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, confirms it will announce its interim results for the six months to 30 September 2022 on 24 November 2022.
Jag Grewal, Chief Executive Officer, and Chris Lea, Chief Financial Officer, will provide a live presentation relating to the Company’s Interim Results via the Investor Meet Company platform on 24 November 2022 at 4:30pm GMT.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Omega Diagnostics Group Plc via:https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor
|Omega Diagnostics Group PLC||www.omegadx.com|
|Jag Grewal Chief Executive Officer||via Walbrook PR|
|Chris Lea, Chief Financial Officer|
|finnCap Ltd||Tel: 020 7220 0500|
|Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)|
|Alice Lane/ Charlotte Sutcliffe (ECM)|
|Walbrook PR Limited||Tel: 020 7933 8780 or [email protected]|
|Paul McManus||Mob: 07980 541 893|
|Sam Allen||Mob: 07502 558 258|
|Lianne Applegarth||Mob: 07584 391 303|
About Omega Diagnostics Group PLC
Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition. www.omegadx.com